Allarity Therapeutics, Inc. Common Stock (ALLR) Stock Price

ALLRStock
$1.416.00%52W
Market Cap$22.43M
P/E
PEG Ratio
Div yield
Beta0.60

ALLR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)36.49%
Price vs S&P 500 (4W)9.48%
VGM Score52.48

ALLR Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.25-$0.21+16.00%(+$0.04)
Q1 2026-$0.22-$0.17+22.73%(+$0.05)
Q4 2025-$0.22-$0.21+4.55%(+$0.01)
Q3 2025-$0.23-$0.19+17.39%(+$0.04)
Q2 2025-$0.21-$0.15+28.57%(+$0.06)

ALLR Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ALLRAllarity Therapeutics, Inc. Common Stock
C$1.41
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Allarity Therapeutics, Inc. Common Stock

Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, an oral small-molecule inhibitor for advanced recurrent ovarian cancer. The company uses its proprietary Drug Response Predictor (DRP) technology to identify patients most likely to benefit from treatment, combining precision medicine with oncology. Operating in Denmark and the United States, Allarity is focused on addressing a significant unmet medical need in ovarian cancer treatment.